Two very common MTHFR variants modestly change how efficiently one folate-processing enzyme works. They are heavily over-claimed online; here is what the published evidence actually supports, and what it does not.
The MTHFR gene carries the instructions for an enzyme called methylenetetrahydrofolate reductase. Its job sits in the middle of the folate pathway: it converts one form of folate (5,10-methylenetetrahydrofolate) into another (5-methyltetrahydrofolate, often shortened to 5-MTHF), which is the main form of folate that circulates in blood. That form is also the methyl donor used to convert homocysteine, an amino acid, back into methionine. So when the enzyme works less efficiently, the practical consequence is a shift in the balance of folate forms and, in some people, a modest rise in blood homocysteine.
Two spots in the MTHFR gene vary commonly between people. The first, rs1801133, is almost always called C677T. The second, rs1801131, is called A1298C. Neither is rare or exotic. In 1000 Genomes data, the C677T "T" version is carried on roughly a third of chromosomes in European-ancestry populations and nearly half in some populations of the Americas; the A1298C "C" version is similarly common. Because they are this frequent, a large share of the world's population carries one or two copies of one or both. That alone is a useful reality check: these are ordinary human variation, not a rare disease finding.
What the evidence does support. The C677T change is the better characterised of the two. The 1995 paper that first described it found that carrying it — in one or two copies — went along with reduced enzyme activity and an enzyme that lost activity more readily when warmed, and that people with two copies had meaningfully higher plasma homocysteine. That basic biochemistry has held up. The effect is also strongly modified by folate intake: people with two copies who have good folate status generally do not show much homocysteine elevation at all. Population studies have also found a small increase in the risk of neural tube defects such as spina bifida and anencephaly associated with this variant. The A1298C change appears milder and less consistent; it is not the variant responsible for the heat-sensitive enzyme, and public variant databases classify it as benign.
What the evidence does not support. This is where MTHFR has gone badly off the rails online. A large amount of marketing presents these variants as an explanation for recurrent miscarriage, blood clots, heart disease, autism, chronic fatigue, and an impaired ability to "detox" — and then sells testing, supplements, or protocols on that basis. Those claims have run well ahead of the data. The American College of Medical Genetics and Genomics reviewed this directly and concluded that meta-analyses had failed to support a causal link between raised homocysteine and coronary heart disease, and had failed to support a link between MTHFR variant status and venous blood clots. Its position was that MTHFR testing has minimal clinical utility and should not be part of a routine workup for clotting disorders. For most other conditions people attach to MTHFR, the honest summary given by MedlinePlus Genetics is that study results have been mixed and the role of MTHFR remains unclear. "Detoxification" in particular is not something the MTHFR enzyme does; that framing has no basis in the gene's known biochemistry.
The folic acid myth specifically. One of the most widely repeated claims is that people with an MTHFR variant cannot use folic acid and must take methylfolate (5-MTHF) instead. The US Centers for Disease Control and Prevention addresses this head-on and says it is not true: people with MTHFR variants can process all forms of folate, including folic acid. On the same intake, people with two copies of the C677T variant average only about 16% lower blood folate than people with none — and how much folic acid someone gets matters more for their folate level than their MTHFR genotype does. Folic acid is also the form with the actual evidence behind neural tube defect prevention, which is why the CDC's guidance on folic acid before and during early pregnancy is not conditioned on genotype.
A different, genuinely rare condition. Severe MTHFR deficiency does exist, but it is not what the common variants cause. It is a rare inherited metabolic disorder caused by two damaging copies of the gene, and it presents very differently — in newborns with poor feeding, small head size, seizures and developmental delay, or later in life with blood clots, dislocated lenses, or neurological and psychiatric changes. It is diagnosed through clinical and biochemical findings plus molecular testing, not by finding a common polymorphism on a consumer genetics report.
This page is educational information about a gene and a body of published research. It is not medical advice, not a diagnosis, and not a basis for starting, stopping, or changing any supplement or medication. Questions about folate status, homocysteine, pregnancy planning, or clotting risk belong with a clinician who can look at the whole picture.
Nomenclature. On the current reference transcript NM_005957.5, rs1801133 is c.665C>T (p.Ala222Val) and rs1801131 is c.1286A>C (p.Glu429Ala). The familiar "C677T" and "A1298C" labels derive from older transcript numbering and remain in near-universal use in the literature and on consumer reports; both naming systems refer to the same two substitutions. Note also that rs1801133 is reported on the minus strand relative to the genomic forward strand, so population databases may display the alleles as G/A.
Functional data. Frosst et al. (Nat Genet 1995;10:111-113) identified the p.Ala222Val substitution, reported reduced MTHFR activity and increased thermolability in lymphocyte extracts for both heterozygotes and homozygotes, confirmed the thermolability effect by in vitro expression of the mutagenised cDNA, and found significantly elevated plasma total homocysteine in homozygotes. Homocysteine elevation associated with the 677TT genotype is folate-status dependent and is attenuated with adequate folate. p.Glu429Ala has a milder and less consistently demonstrated effect on enzyme activity, is not associated with the thermolabile phenotype, and is aggregated in ClinVar with a benign/likely benign germline classification. Compound heterozygosity (677CT/1298AC) is frequently cited as producing an intermediate reduction in activity, but the published findings on its homocysteine effect are not uniform and it should not be treated as equivalent to 677TT.
Genotype frequency context. 1000 Genomes Phase 3 allele frequencies (Ensembl) for the 677T allele: EUR 0.365, AMR 0.474, EAS 0.296, SAS 0.119, AFR 0.090. For the 1298C allele: SAS 0.417, EUR 0.313, EAS 0.219, AFR 0.151, AMR 0.151. At the European-ancestry 677T frequency, Hardy-Weinberg expectation puts 677TT homozygosity on the order of one in eight — i.e. a genotype far too common to function as a rare-disease explanation for an individual patient's presentation.
Guideline position. Hickey SE, Curry CJ, Toriello HV; ACMG Professional Practice and Guidelines Committee. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15(2):153-156. The document states that meta-analyses have not supported an association between hyperhomocysteinaemia and coronary heart disease risk, and between MTHFR polymorphism status and venous thromboembolism risk, and concludes that MTHFR polymorphism testing has minimal clinical utility and should not be ordered as part of a routine thrombophilia evaluation. It was reaffirmed by the ACMG Board in April 2020 and, in the accompanying addendum (Genet Med. 2020;22:2125), reclassified from an evidence-based practice guideline to a Clinical Practice Resource because it no longer met the College's criteria for the former category — a reclassification of document type, not a reversal of its conclusions.
Distinguishing severe MTHFR deficiency. Homocystinuria due to deficiency of N(5,10)-methylenetetrahydrofolate reductase activity is an autosomal recessive disorder established by suggestive clinical and biochemical findings together with biallelic pathogenic or likely pathogenic MTHFR variants (GeneReviews, NBK615089). Presentations range from neonatal onset with postnatal microcephaly, feeding difficulty, seizures, apnoea and progressive neurological deterioration, to adolescent or adult onset with thromboembolism, lens dislocation, and less often cognitive, psychiatric, seizure or gait manifestations. The causative alleles are rare loss-of-function variants, categorically distinct from c.665C>T and c.1286A>C.
Pharmacogenomic status. MTHFR is not among the genes covered by any current CPIC gene-drug guideline. It has been studied in relation to methotrexate toxicity — ClinVar carries an expert-panel drug-response entry for c.665C>T on that phenotype — but that association has not been translated into a CPIC prescribing guideline, and MTHFR genotype should not be treated as an actionable pharmacogenomic result on the strength of that entry alone.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about MTHFR Variants and Folate Metabolism comes down to these specific, well-studied positions — not a diagnosis.
No — this is the single most widely repeated MTHFR myth, and the CDC addresses it directly: people with MTHFR variants can process all forms of folate, including folic acid. On the same intake, people with two copies of C677T average only about 16% lower blood folate than people with none, and total folic acid intake matters more for folate level than genotype does. Folic acid is also the form with the evidence behind neural tube defect prevention. Any decision about supplements is one to make with a clinician, not on the basis of a genotype alone.
That was the original hypothesis, and it did not hold up. The ACMG reviewed the evidence and reported that meta-analyses had not supported an association between raised homocysteine and coronary heart disease risk, and between MTHFR variant status and venous thromboembolism. Its conclusion was that MTHFR testing has minimal clinical utility and should not be part of a routine workup for clotting disorders. Recurrent pregnancy loss has many possible causes and warrants a proper clinical evaluation rather than a single genotype.
These are not established. MTHFR is a folate-pathway enzyme; detoxification is not a function it performs, so that framing has no basis in the gene's known biochemistry. For most conditions people attach to MTHFR beyond the rare severe deficiency, MedlinePlus Genetics summarises the literature as mixed, with associations found in some studies and not others, leaving the role of MTHFR unclear.
It changes one amino acid in the enzyme, producing a version that is somewhat less active and that loses activity more readily when warmed. People with two copies tend to have modestly higher blood homocysteine — an effect that is strongly buffered by good folate status, so it is often minimal in people getting enough folate. Population studies have also linked it to a small increase in neural tube defect risk.
No, and conflating the two is a common source of alarm. Severe MTHFR deficiency is a rare autosomal recessive metabolic disorder caused by two damaging copies of the gene, diagnosed through clinical and biochemical findings plus molecular testing. The common C677T and A1298C variants are ordinary population variation carried by a large fraction of people worldwide and are not the cause of that disorder.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.